KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Finished Goods: 2010-2023

Historic Finished Goods for Nektar Therapeutics (NKTR) over the last 11 years, with Dec 2023 value amounting to $1.4 million.

  • Nektar Therapeutics' Finished Goods was N/A to $2.2 million in Q2 2024 from the same period last year, while for Jun 2024 it was $2.2 million, marking a year-over-year change of. This contributed to the annual value of $1.4 million for FY2023, which is 76.86% down from last year.
  • Latest data reveals that Nektar Therapeutics reported Finished Goods of $1.4 million as of FY2023, which was down 76.86% from $5.9 million recorded in FY2022.
  • In the past 5 years, Nektar Therapeutics' Finished Goods registered a high of $5.9 million during FY2022, and its lowest value of $1.4 million during FY2023.
  • For the 2-year period, Nektar Therapeutics' Finished Goods averaged around $3.6 million, with its median value being $3.6 million (2022).
  • Data for Nektar Therapeutics' Finished Goods shows a maximum YoY tumbled of 76.86% (in 2023) over the last 5 years.
  • Over the past 2 years, Nektar Therapeutics' Finished Goods (Yearly) stood at $5.9 million in 2022, then tumbled by 76.86% to $1.4 million in 2023.